Omid Hamid/globaloncologyacademy.org
Feb 28, 2025, 13:46
Omid Hamid: CTLA-4 Conditionally Active shows tolerability with full dose Nivolumab
Omid Hamid, Chief of Clinical Translational Research and Immunotherpeutics at the Angeles Clinic and Research Insititute, shared a post on X:
“AACR IO in Los Angeles BioAtl CTLA-4 Conditionally Active shows tolerability with full dose Nivolumab Bristol Myers Squibb stressing the need to continue to develop CTLA4 – great meeting led by Toni Ribas.”
Ankit Mangla, Sarcoma and Cutaneous Oncology Specialist at the Seidman Cancer Center, shared this post, adding:
“Congratulations to team Bioatl. We need next generation anti-CTLA4 to ensure better delivery and higher efficacy.”
More posts featuring Omid Hamid and Ankit Mangla.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 30, 2025, 23:21
Mar 30, 2025, 18:52
Mar 30, 2025, 18:31